Skip to main content

Table 3 Characteristics of interventional trials by funding sources, 2008–2019

From: Updated analysis of pediatric clinical studies registered in ClinicalTrials.gov, 2008–2019

 

Trials, No.(%)

χ2

P value

Industry-funded

(n = 7,867)

NIH-funded

(n = 2,641)

Other

(n = 21,394)

Founding sites

   

6,181.2

<  0.001

 Single-site

2,786(35.4)

1,656(62.7)

17,734(82.9)

  

 Multisite

5,081(64.6)

985(37.3)

3,660(17.1)

  

Status_Completed

   

283.1

<  0.001a

 Yes

4,817(61.2)

1,352(51.2)

10,747(50.2)

  

 No

3,050(38.8)

1,289(48.8)

10,647(49.8)

  

Primary purpose_treatment

   

641.6

<  0.001b

 Yes

5,585(71.0)

1,478(56.0)

11,698(54.7)

  

 No

2,282(29.0)

1,163(44.0)

9,696(45.3)

  

Intervention_Drug

   

4,043.9

<  0.001

 Yes

4,637(58.9)

964(36.5)

4,341(20.3)

  

 No

3,230(41.1)

1,677(63.5)

17,053(79.7)

  

Phase_phase 3–4

   

2,296.7

<  0.001

 Yes

3,230(41.1)

320(12.1)

3,399(15.9)

  

 No

4,637(58.9)

2,321(87.9)

17,995(84.1)

  
  1. χ2 test for effect of funding sources (industry, NIH, or other) influencing proportion of trials
  2. aMultiple comparisons: NIH-funded vs Other adjusted p value = 0.360, p <  0.001 for those not specifically noted (adjustment method: fdr)
  3. bMultiple comparisons: NIH-funded vs Other adjusted p value = 0.220, p <  0.001 for those not specifically noted (adjustment method: fdr)